EUZ

ECKERT+ZIEGLER AG O.N.

Stock XETRA – Stock Market Prices, News & Analysis

Eckert & Ziegler AG specializes in radioactive components for medical treatment, medical imaging, and industrial applications.

€ 15.45
1.15 %

ECKERT+ZIEGLER AG O.N.

15.45
1.15 %
EUZ

Eckert & Ziegler AG specializes in radioactive components for medical treatment, medical imaging, and industrial applications.

Price history of ECKERT+ZIEGLER AG O.N.
Price history of ECKERT+ZIEGLER AG O.N.

Performance & Momentum

6 Months 10.07 %
1 Year 12.69 %
3 Years 21.24 %
5 Years 30.39 %

Strategic Analysis

ECKERT+ZIEGLER AG O.N. • 2026

Eckert & Ziegler AG is a niche player in the healthcare sector, specializing in the production of radioactive components intended for medical treatments, imaging, and industrial applications. Its business model relies on advanced technological expertise and a stable position in highly specialized markets where entry barriers are high.

Strengths
  • Unique positioning in a specialized high-value medical segment
  • Diversified portfolio covering both medical and industrial applications
  • Recognized expertise in the handling and production of radioactive materials
Weaknesses
  • Sensitivity to regulatory cycles and legal constraints in the medical sector
  • Deteriorated stock performance in recent years, reflecting operational or market challenges
Momentum

The current momentum is weak, illustrating prolonged downward pressure and a lack of visible short-term catalysts. The absence of recent news underscores the need for increased vigilance before making any position, even though the technical specialization could represent recovery potential in the medium term.

Similar stocks to ECKERT+ZIEGLER AG O.N.

Was this page helpful?

Your feedback helps us improve our research.

Take control
of your investments

Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.

  • Real-time multi-portfolio tracking
  • AI analysis of your positions
  • Counter your cognitive biases
Anantys Invest on iPhone